(202) 599-8435

Sales of Naltrexone Skyrocket with Little Evidence To Support Its Use

Not a single published trial has compared long-acting naltrexone to methadone or buprenorphine for the treatment of opioid use disorder. Long-acting naltrexone’s appeal is largely its physical blockade of opioids, with the medicine locking up receptors in the brain the same way society locks up drug offenders. Worse still is the possibility that long-acting naltrexone treatment may actually increase the risk for overdose. Read more here.

Print Friendly
About the Author